HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

4-Aminopyridine (4 Aminopyridine)

One of the POTASSIUM CHANNEL BLOCKERS, with secondary effect on calcium currents, which is used mainly as a research tool and to characterize channel subtypes.
Also Known As:
4 Aminopyridine; 4-Aminopyridine Sustained Release; Fampridine-SR; Pymadine; VMI-103; 4 Aminopyridine Sustained Release; Fampridine SR; Sustained Release, 4-Aminopyridine; VMI 103; VMI103; 4-Pyridinamine
Networked: 495 relevant articles (36 outcomes, 67 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Mihály, András: 10 articles (05/2015 - 02/2003)
2. Krisztin-Péva, Beáta: 8 articles (01/2015 - 02/2003)
3. Rothman, Steven M: 8 articles (01/2012 - 03/2002)
4. Avoli, Massimo: 7 articles (06/2015 - 12/2007)
5. Yang, Xiao-Feng: 7 articles (01/2010 - 03/2002)
6. Heinemann, Uwe: 6 articles (08/2014 - 10/2009)
7. Tapia, Ricardo: 6 articles (07/2014 - 10/2003)
8. Strupp, Michael: 5 articles (04/2015 - 09/2011)
9. Blight, Andrew R: 5 articles (11/2014 - 07/2003)
10. Medina-Ceja, Laura: 5 articles (07/2012 - 01/2008)

Related Diseases

1. Multiple Sclerosis
2. Seizures (Seizure)
3. Spinal Cord Injuries (Spinal Cord Injury)
4. Alzheimer Disease (Alzheimer's Disease)
5. Pathologic Nystagmus
02/01/2011 - "Controlled studies found gabapentin and memantine to be effective in acquired pendular nystagmus and early-onset idiopathic nystagmus, and an efficacy of 4-aminopyridine in downbeat nystagmus."
02/01/2015 - "PHARMACOLOGICAL TREATMENT: Depending on the pathophysiology of different types of nystagmus, several drugs were effective in clinical application (off-label use): (i) gabapentin (non-selective GABAergic and anti-glutamatergic effect): up to 2400 mg/d in infantile nystagmus, acquired pendular nystagmus and oculopalatal tremor, (ii) nemantine (anti-glutamatergic effect): dosage up to 40 mg/d in infantile nystagmus, also in acquired pendular nystagmus and oculopalatal tremor, (iii) baclofen (GABA-B-receptor agonist): 3 × 5-10 mg/d in periodic alternating nystagmus and in upbeat nystagmus, (iv) 4-aminopyridine (non-selective blocker of voltage-gated potassium channels): 3 × 5 mg/d or 1-2 × 10 mg Fampridin in downbeat nystagmus and upbeat nystagmus, (v) acetazolamide (carbonic anhydrase inhibitor): in hereditary episodic ataxia type 2. OPTICAL DEVICES: (i) Contact lenses are used in infantile nystagmus in order to overcome negative effects of eye glasses in abnormal head posture, lateral gaze, and higher refractive errors, (ii) spectacle prisms are useful to induce an artificial exophoria (base-out prisms) or to shift an excentric null zone (base in direction of head posture) of infantile nystagmus with abnormal head posture, (iii) low vision aids may be necessary and should be prescribed according to magnification requirements."

Related Drugs and Biologics

1. N-Methylaspartate (NMDA)
2. Kainic Acid (Kainate)
3. Potassium Channels (Potassium Channel)
4. Pentylenetetrazole (Metrazol)
5. gabapentin (Neurontin)
6. alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
7. Episodic ataxia with nystagmus
8. Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)
9. Verapamil (Calan)
10. Pilocarpine (Ocusert)

Related Therapies and Procedures

1. Intravenous Infusions
2. Off-Label Use
3. Optical Devices
4. Contact Lenses
5. Oral Administration